CAR and Antibodies Structure-Activity Relationships and molecular architecture

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Abstract

We apply biophysical methods to characterize the structure and dynamic properties of the CD28 CAR hinge (CD28H) used in an FDA-approved CD19 CAR for the treatment of B-lineage leukemia/lymphoma. Our study demonstrates a method for detecting local and transient structure within intrinsically disordered systems and moreover, our CD28H findings may inform future CAR design. We also developed chimeric adaptor proteins (CAPs) and CAR tyrosine kinases (CAR-TKs) in which the intracellular zeta T cell receptor (TCRzeta) chain was replaced with intracellular protein domains to stimulate signaling downstream of the TCRzeta chain. This project was closed in March 2025.